The Ehlers-Danlos syndromes are hereditary connective-tissue disorders; the vascular type (vEDS), caused by defective type III collagen, is the most dangerous owing to a high risk of arterial dissection and rupture. Management is individualized, spanning vascular prevention, chronic pain, and quality of life.
Vascular event prevention in vEDS
Celiprolol, a beta-1-selective blocker with beta-2 vasodilatory activity, is the best-supported agent: the open-label randomized BBEST trial and observational data showed a reduction in arterial events, and it is now considered established therapy for vEDS. The key recent addition comes from a randomized, placebo-controlled trial showing that adding the ARB irbesartan to background celiprolol further reduced vascular events, supporting combination therapy — though hypotension, bradycardia, and electrolyte changes can limit dosing. Agents targeting extracellular matrix organization remain investigational.
Chronic pain and general management
Physical and occupational therapy — focused on strengthening, proprioception, and joint stabilization — are core across all EDS types. Low-dose naltrexone shows early promise for chronic pain with few side effects, and cognitive behavioral therapy, laser therapy, and (for hypermobility-related instability) prolotherapy are used adjunctively. Lifestyle modification, protective strategies, and specialized wound care (non-adherent dressings, attention to skin fragility) reduce injury risk, and complications such as aneurysm or chylous ascites require multidisciplinary input. Mesenchymal stromal cell therapy for severe wounds remains experimental.
| Intervention | Indication | Evidence |
|---|---|---|
| Celiprolol | vEDS vascular prevention | Reduced arterial events (BBEST) |
| Irbesartan + celiprolol | vEDS | Further risk reduction (randomized trial) |
| Physical/occupational therapy | All EDS | Improved stability and function |
| Low-dose naltrexone | Chronic pain | Early positive evidence |
| Lifestyle & wound care | General | Injury prevention |
Further reading: celiprolol BBEST trial and vEDS management reviews (2023–2024); irbesartan added to celiprolol (Jeunemaitre et al., Circulation 2025); low-dose naltrexone scoping review (2023).